Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been given a $182.00 price target by research analysts at Leerink Swann in a note issued to investors on Wednesday. The brokerage presently has a a “buy” rating on the specialty pharmaceutical company’s stock. Leerink Swann’s price objective suggests a potential upside of 59.22% from the company’s previous close.

A number of other research firms have also recently commented on JAZZ. BMO Capital Markets reaffirmed an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Sunday, July 31st. Barclays PLC reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 10th. Piper Jaffray Cos. dropped their price objective on Jazz Pharmaceuticals PLC from $188.00 to $178.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 10th. Mizuho dropped their price objective on Jazz Pharmaceuticals PLC from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, August 10th. Finally, Zacks Investment Research cut Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, July 20th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $178.25.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 114.31 on Wednesday. The firm has a 50 day moving average price of $118.10 and a 200-day moving average price of $135.73. The company has a market cap of $6.92 billion, a price-to-earnings ratio of 20.10 and a beta of 1.35. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $160.00.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 EPS for the quarter, missing analysts’ consensus estimates of $2.61 by $0.04. The business had revenue of $374 million for the quarter, compared to the consensus estimate of $389.34 million. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.50%. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.52 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post $10.05 earnings per share for the current fiscal year.

In related news, Director Seamus Mulligan sold 27,968 shares of the firm’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $128.32, for a total value of $3,588,853.76. Following the completion of the transaction, the director now owns 1,072,411 shares in the company, valued at approximately $137,611,779.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $126.17, for a total value of $25,234.00. Following the completion of the transaction, the senior vice president now owns 17,325 shares of the company’s stock, valued at approximately $2,185,895.25. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the company. BlueMountain Capital Management LLC raised its position in shares of Jazz Pharmaceuticals PLC by 72.7% in the first quarter. BlueMountain Capital Management LLC now owns 7,217 shares of the specialty pharmaceutical company’s stock worth $942,000 after buying an additional 3,039 shares during the period. Avalon Advisors LLC raised its position in shares of Jazz Pharmaceuticals PLC by 13.7% in the first quarter. Avalon Advisors LLC now owns 9,320 shares of the specialty pharmaceutical company’s stock worth $1,217,000 after buying an additional 1,120 shares during the period. Seven Eight Capital LLC purchased a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth about $574,000. Bellevue Group AG purchased a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth about $8,159,000. Finally, Springbok Capital Management LLC raised its position in shares of Jazz Pharmaceuticals PLC by 21.8% in the first quarter. Springbok Capital Management LLC now owns 2,120 shares of the specialty pharmaceutical company’s stock worth $277,000 after buying an additional 380 shares during the period. Institutional investors own 88.35% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.